Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid
- PMID: 14711073
- DOI: 10.1016/s0891-5520(03)00065-5
Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid
Abstract
Time above MIC for free drug concentrations is the important PK-PD parameter correlating with the efficacy of beta-lactam antibiotics. The duration of time plasma concentrations needed to exceed the MIC is relatively similar for most organisms except staphylococci. Neutrophils contribute very little to the overall activity of beta-lactams. The appearance of increasing antimicrobial resistance can challenge the efficacy of these drugs when concentrations do not exceed the MIC for 40% to 50% of the dosing interval. Time above MIC with oral amoxicillin and amoxicillin-clavulanate can be enhanced with high-dose formulations. Time above MIC with parenteral preparations can be enhanced by longer intravenous infusions or even continuous infusion. The 24-hour AUC-MIC is probably the important PK-PD parameter correlating with the efficacy of vancomycin and teicoplanin. It clearly is the important parameter for the efficacy of linezolid. Usual doses of these drugs generally provide adequate plasma concentrations to treat effectively infections in which plasma concentrations are predictive of tissue concentrations. Penetration of these drugs into respiratory secretions, such as ELF, is enhanced for linezolid and reduced for vancomycin. This may give linezolid an advantage over vancomycin in certain respiratory infections.
Similar articles
-
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.Clin Pharmacokinet. 2003;42(15):1411-23. doi: 10.2165/00003088-200342150-00007. Clin Pharmacokinet. 2003. PMID: 14674791
-
Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.Antimicrob Agents Chemother. 2006 Dec;50(12):4011-7. doi: 10.1128/AAC.00523-06. Epub 2006 Oct 2. Antimicrob Agents Chemother. 2006. PMID: 17015630 Free PMC article.
-
Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.J Antimicrob Chemother. 2003 May;51 Suppl 2:ii17-25. doi: 10.1093/jac/dkg248. J Antimicrob Chemother. 2003. PMID: 12730139 Review.
-
Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.Clin Microbiol Infect. 2008 Feb;14(2):116-23. doi: 10.1111/j.1469-0691.2007.01885.x. Epub 2007 Dec 10. Clin Microbiol Infect. 2008. PMID: 18076672
-
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.Clin Pharmacokinet. 1995 Feb;28(2):143-60. doi: 10.2165/00003088-199528020-00005. Clin Pharmacokinet. 1995. PMID: 7736689 Review.
Cited by
-
Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure-Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli.Antibiotics (Basel). 2021 May 21;10(6):615. doi: 10.3390/antibiotics10060615. Antibiotics (Basel). 2021. PMID: 34063980 Free PMC article.
-
Individualized Vancomycin Dosing with Therapeutic Drug Monitoring and Pharmacokinetic Consultation Service: A Large-Scale Retrospective Observational Study.Drug Des Devel Ther. 2021 Mar 4;15:423-440. doi: 10.2147/DDDT.S285488. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 33692613 Free PMC article.
-
Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2005 Oct;49(10):4344-6. doi: 10.1128/AAC.49.10.4344-4346.2005. Antimicrob Agents Chemother. 2005. PMID: 16189117 Free PMC article.
-
Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb. Antimicrob Agents Chemother. 2019. PMID: 30455232 Free PMC article.
-
WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model.Antimicrob Agents Chemother. 2019 Sep 9;63(12):e01648-19. doi: 10.1128/AAC.01648-19. Epub 2019 Oct 7. Antimicrob Agents Chemother. 2019. PMID: 31591114 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical